Plat (plasminogen activator, tissue type) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Plat (plasminogen activator, tissue type) Rattus norvegicus
Symbol: Plat
Name: plasminogen activator, tissue type
RGD ID: 3342
Description: Predicted to enable phosphoprotein binding activity; serine-type endopeptidase activity; and signaling receptor binding activity. Involved in several processes, including cellular response to hormone stimulus; plasminogen activation; and prevention of polyspermy. Located in extracellular space. Is active in several cellular components, including glutamatergic synapse; neuronal dense core vesicle; and perisynaptic space. Used to study disseminated intravascular coagulation and status epilepticus. Biomarker of brain edema; middle cerebral artery infarction; sciatic neuropathy; transient cerebral ischemia; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in several diseases, including antiphospholipid syndrome; diabetic angiopathy; factor VIII deficiency; osteonecrosis; and von Willebrand's disease 1. Orthologous to human PLAT (plasminogen activator, tissue type); PARTICIPATES IN acenocoumarol pharmacodynamics pathway; alteplase pharmacodynamics pathway; aminocaproic acid pharmacodynamics pathway; INTERACTS WITH (+)-catechin; (S)-colchicine; 1-naphthyl isothiocyanate.
Type: protein-coding
Previously known as: LOC100910418; PATISS; plasminogen activator, tissue; t-PA; t-plasminogen activator; tissue plasminogen activator; tissue-type plasminogen activator; tissue-type plasminogen activator-like; tPA
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81675,943,061 - 76,022,037 (-)NCBIGRCr8
mRatBN7.21669,240,582 - 69,265,177 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1669,240,585 - 69,268,223 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1674,514,320 - 74,538,910 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01677,946,850 - 77,971,428 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01673,195,994 - 73,220,572 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01674,098,263 - 74,122,897 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1674,098,260 - 74,122,889 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01673,730,256 - 73,754,851 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41673,711,323 - 73,736,328 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11673,711,587 - 73,736,593 (-)NCBI
Celera1667,134,451 - 67,159,047 (-)NCBICelera
RH 3.4 Map16644.8RGD
Cytogenetic Map16q12.5NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (ISO)
acute promyelocytic leukemia  (ISO)
Acute Traumatic Coagulopathy  (IDA,IEP)
Airway Obstruction  (ISO)
allergic contact dermatitis  (ISO)
amphetamine abuse  (ISO)
angioedema  (ISO)
antiphospholipid syndrome  (ISO)
aphasia  (ISO)
Arterial Occlusive Diseases  (ISO)
Arterial Thrombosis  (ISO)
atherosclerosis  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
Back Pain  (ISO)
Bacteremia  (ISO)
blood coagulation disease  (ISO)
brain edema  (IEP,ISO)
Brain Hypoxia-Ischemia  (IEP)
brain infarction  (ISO)
brain ischemia  (ISO)
Burns  (ISO)
cardiac tamponade  (ISO)
Cardiogenic Shock  (ISO)
Carotid Artery Injuries  (IEP)
Central Nervous System Viral Diseases  (IEP)
Cerebral Hemorrhage  (IDA,ISO)
cerebral infarction  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
cholesterol embolism  (ISO)
Chronic Hepatitis  (ISO)
congestive heart failure  (ISO)
coronary thrombosis  (ISO)
diabetic angiopathy  (ISO)
Diabetic Foot  (ISO)
Diabetic Nephropathies  (ISO)
diabetic neuropathy  (ISO)
disseminated intravascular coagulation  (IDA,ISO)
Embolism  (ISO)
Embolism and Thrombosis  (ISO)
Endotoxemia  (ISO)
Experimental Liver Cirrhosis  (IDA,ISO)
factor VIII deficiency  (ISO)
Femur Head Necrosis  (ISO)
genetic disease  (ISO)
gestational diabetes  (ISO)
hemolytic-uremic syndrome  (ISO)
Hemorrhage  (ISO)
hemorrhagic disease  (ISO)
Henoch-Schoenlein purpura  (ISO)
hypertension  (ISO)
Hypotension  (ISO)
Hypoxia  (ISO)
immunodeficiency 15B  (ISO)
Intracranial Embolism and Thrombosis  (ISO)
Intracranial Hemorrhages  (ISO)
intracranial thrombosis  (ISO)
intracranial vasospasm  (ISO)
lactic acidosis  (ISO)
leukopenia  (ISO)
Low Back Pain  (ISO)
meningoencephalitis  (ISO)
Metabolic Syndrome  (ISO)
middle cerebral artery infarction  (IEP,ISO)
Multiple Organ Failure  (IEP)
myocardial infarction  (ISO)
Nerve Degeneration  (ISO)
Neurologic Manifestations  (ISO)
Noonan syndrome  (ISO)
obesity  (ISO)
pancreatic adenocarcinoma  (ISO)
Paresis  (ISO)
pericardial effusion  (ISO)
peritonitis  (ISO)
pulmonary embolism  (ISO)
Reperfusion Injury  (IDA,ISO)
respiratory failure  (ISO)
Right Ventricular Hypertrophy  (IEP)
sciatic neuropathy  (IEP)
Sepsis  (IDA)
severe acute respiratory syndrome  (ISO)
Spinal Cord Compression  (ISO)
Spinal Epidural Hematoma  (ISO)
status epilepticus  (IDA)
Stroke  (ISO)
Subdural Hematoma  (ISO)
Thromboembolism  (ISO)
thrombosis  (ISO)
torsion dystonia 6  (ISO)
toxic encephalopathy  (ISO)
transient cerebral ischemia  (IEP)
Transplant Rejection  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (IEP,ISO)
Venous Thromboembolism  (ISO)
Venous Thrombosis  (ISO)
Ventricular Dysfunction, Left  (ISO)
von Willebrand's disease 1  (ISO)
Wounds and Injuries  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (EXP,ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(1->4)-beta-D-glucan  (ISO)
(S)-colchicine  (EXP)
(S)-nicotine  (ISO)
1,2-dimethylhydrazine  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
1-naphthyl isothiocyanate  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3',4,4',5-Pentachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (ISO)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2-amino-2-deoxy-D-glucopyranose  (ISO)
2-palmitoylglycerol  (ISO)
2-trans,6-trans,10-trans-geranylgeranyl diphosphate  (EXP)
3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
8-Br-cAMP  (ISO)
9-cis-retinoic acid  (ISO)
acetamide  (EXP)
actinomycin D  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucosamine  (ISO)
aldehydo-D-glucose  (ISO)
aldosterone  (EXP)
all-trans-4-oxoretinoic acid  (ISO)
all-trans-retinoic acid  (EXP,ISO)
aminoguanidine  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (EXP)
aristolochic acid A  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
beta-carotene  (ISO)
beta-D-glucosamine  (ISO)
beta-naphthoflavone  (ISO)
bexarotene  (ISO)
bis(2-chloroethyl) sulfide  (EXP)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bucladesine  (ISO)
butan-1-ol  (ISO)
butanal  (ISO)
Butylbenzyl phthalate  (ISO)
butyric acid  (EXP)
cadmium atom  (ISO)
cadmium dichloride  (EXP)
calciol  (ISO)
cannabidiol  (ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
CGP 52608  (ISO)
chloroprene  (ISO)
choline  (ISO)
chromium(6+)  (ISO)
chrysene  (ISO)
cisplatin  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
copper(II) sulfate  (ISO)
Cuprizon  (EXP)
cycloheximide  (EXP)
cyclosporin A  (ISO)
cytarabine  (ISO)
cytochalasin D  (ISO)
D-glucose  (ISO)
daunorubicin  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
dibenzo[a,l]pyrene  (ISO)
dibutyl phthalate  (EXP,ISO)
dichlorine  (EXP)
dienogest  (ISO)
diethyl maleate  (EXP,ISO)
diethyl phthalate  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dioxygen  (ISO)
dipyridamole  (ISO)
diuron  (EXP)
dorsomorphin  (EXP,ISO)
doxorubicin  (ISO)
edaravone  (EXP)
endosulfan  (EXP)
ethanol  (EXP,ISO)
Ethyl icosapentate  (EXP)
ethylenediaminetetraacetic acid  (ISO)
eugenol  (ISO)
fenbuconazole  (ISO)
folic acid  (ISO)
fructose  (ISO)
fulvestrant  (ISO)
furan  (EXP)
genistein  (EXP,ISO)
gentamycin  (EXP)
geranylgeraniol  (ISO)
gestodene  (ISO)
glucose  (ISO)
Goe 6976  (ISO)
GW 4064  (ISO)
heparin  (ISO)
hydrogen peroxide  (ISO)
icatibant  (ISO)
indometacin  (ISO)
irinotecan  (EXP,ISO)
isobutanol  (ISO)
isoprenaline  (EXP)
isotretinoin  (ISO)
ketamine  (EXP)
KT 5823  (ISO)
L-ascorbic acid  (EXP)
L-methionine  (ISO)
lead diacetate  (EXP)
levonorgestrel  (ISO)
lipopolysaccharide  (EXP,ISO)
losartan  (EXP)
lovastatin  (EXP,ISO)
malathion  (ISO)
medroxyprogesterone acetate  (ISO)
metformin  (ISO)
methamphetamine  (EXP,ISO)
methimazole  (EXP)
methotrexate  (ISO)
mevalonic acid  (EXP,ISO)
mifepristone  (EXP,ISO)
mitoxantrone  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
morphine  (ISO)
N-acetylsphingosine  (ISO)
N-nitrosodimethylamine  (EXP)
naphthalene  (ISO)
nickel sulfate  (ISO)
nicotine  (ISO)
nitric oxide  (ISO)
nonanedioic acid  (ISO)
norgestimate  (ISO)
notoginsenoside R1  (ISO)
oxaliplatin  (EXP)
ozone  (EXP)
panobinostat  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
pentanal  (ISO)
pentane-2,3-dione  (EXP)
perfluorohexanesulfonic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenobarbital  (ISO)
phenylmercury acetate  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
pirinixic acid  (ISO)
piroxicam  (ISO)
potassium chromate  (ISO)
prednisone  (ISO)
procymidone  (EXP)
progesterone  (ISO)
propanal  (ISO)
protoporphyrin  (ISO)
quercetin  (EXP,ISO)
raloxifene  (ISO)
resveratrol  (EXP,ISO)
rifampicin  (ISO)
Ro 41-5253  (ISO)
rofecoxib  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
SCH 23390  (EXP,ISO)
silicon dioxide  (ISO)
simvastatin  (EXP,ISO)
sodium arsenite  (ISO)
Soman  (EXP)
sotalol  (EXP)
sotorasib  (ISO)
spironolactone  (ISO)
sulfadimethoxine  (EXP)
sulforaphane  (ISO)
sulindac  (ISO)
tacrolimus hydrate  (ISO)
temozolomide  (ISO)
testosterone  (EXP,ISO)
tetrachloromethane  (ISO)
tetraethyllead  (EXP)
tetraphene  (ISO)
thioacetamide  (EXP)
titanium dioxide  (EXP,ISO)
toluene  (EXP)
topotecan  (EXP)
trametinib  (ISO)
Trapidil  (EXP)
triadimefon  (EXP)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
urethane  (ISO)
valproic acid  (EXP,ISO)
vincaleukoblastine  (EXP)
vinclozolin  (EXP)
vincristine  (EXP)
vitamin E  (EXP)
vorinostat  (ISO)
zearalenone  (ISO)
zinc atom  (EXP,ISO)
zinc(0)  (EXP,ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function


References - curated
# Reference Title Reference Citation
1. Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. Adhami F, etal., Am J Pathol. 2008 Jun;172(6):1704-16. Epub 2008 May 8.
2. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. Agostoni A, etal., Circulation. 1994 Dec;90(6):2666-70.
3. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. Alizadeh Dehnavi R, etal., Eur J Intern Med. 2008 Mar;19(2):115-21. Epub 2007 Nov 5.
4. Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists. Allan EH, etal., Biochim Biophys Acta. 1986 Sep 19;888(2):199-207.
5. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. Aoki K, etal., Burns. 2001 Sep;27(6):569-75.
6. Secretion of cardiac plasminogen activator during hypoxia-induced right ventricular hypertrophy. Bansal DD, etal., J Mol Cell Cardiol. 1997 Nov;29(11):3105-14.
7. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura. Besbas N, etal., Clin Exp Rheumatol. 1998 Jan-Feb;16(1):95-8.
8. Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. Buyne OR, etal., Surgery. 2008 Jul;144(1):66-73. Epub 2008 May 21.
9. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. Chandler WL, etal., N Engl J Med. 2002 Jan 3;346(1):23-32.
10. [Expression of plasminogen activator inhibitor-1 and tissue plasminogen activator in the kidney of KKAy mice with type 2 diabetes] Chen LM, etal., Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Jun;27(3):344-8.
11. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Cugno M, etal., Blood. 2004 Mar 15;103(6):2121-6. Epub 2003 Nov 20.
12. The structure of the TATA-less rat tissue-type plasminogen activator gene. Species-specific sequence divergences in the promoter predict differences in regulation of gene expression. Feng P, etal., J Biol Chem 1990 Feb 5;265(4):2022-7.
13. Prevalence of genetic risk factors related with thrombophilia and hypofibrinolysis in patients with osteonecrosis of the femoral head in Poland. Gagala J, etal., BMC Musculoskelet Disord. 2013 Sep 11;14:264. doi: 10.1186/1471-2474-14-264.
14. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
15. Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor. Gelehrter TD, etal., Mol Endocrinol. 1987 Jan;1(1):97-101.
16. New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Glowinska B, etal., Atherosclerosis. 2003 Apr;167(2):275-86.
17. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
18. Microvascular tissue plasminogen activator is reduced in diabetic neuropathy. Hafer-Macko CE, etal., Neurology. 2007 Jul 17;69(3):268-74.
19. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Hagiwara H, etal., Thromb Res. 2003;111(4-5):301-9.
20. Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia. Haj MA, etal., Br J Haematol. 1995 Jul;90(3):541-7.
21. Increased plasma tissue-type plasminogen activator levels in patients with chronic thrombocytopenia. Hanss M, etal., Haemostasis. 1990;20(6):341-6.
22. Noble-Collip Drum Trauma Induces Disseminated Intravascular Coagulation But Not Acute Coagulopathy of Trauma-Shock. Hayakawa M, etal., Shock. 2015 Mar;43(3):261-7. doi: 10.1097/SHK.0000000000000281.
23. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Hijazi N, etal., Blood. 2015 Apr 16;125(16):2558-67. doi: 10.1182/blood-2014-08-588442. Epub 2015 Feb 11.
24. Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. Hilberg T, etal., Thromb Haemost. 2003 Dec;90(6):1065-73.
25. Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome. Imperatore F, etal., Intensive Care Med. 2006 Nov;32(11):1881-8. Epub 2006 Sep 15.
26. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Jackson CL, etal., Arterioscler Thromb. 1993 Aug;13(8):1218-26.
27. Enhanced tissue plasminogen activator synthesis by the sympathetic neurons that innervate aging vessels. Jiang X, etal., J Neurosci Res 2003 Feb 15;71(4):567-74.
28. Fibrinolytic gene polymorphism and ischemic stroke. Jood K, etal., Stroke. 2005 Oct;36(10):2077-81. Epub 2005 Sep 22.
29. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Kalani M, etal., Thromb Res. 2007;120(5):653-61. Epub 2007 Feb 2.
30. Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease. Kamgar M, etal., Kidney Int. 2006 May;69(10):1899-903.
31. Effect of troglitazone on serum gamma-glutamyltransferase activity and plasma t-PA/PAI-1 complex in type 2 diabetic patients. Koh H, etal., Arzneimittelforschung. 2006;56(4):288-94.
32. Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland. Kristensen P, etal., J Cell Biol. 1985 Jul;101(1):305-11.
33. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
34. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Ladenvall P, etal., Thromb Haemost. 2002 Jan;87(1):105-9.
35. Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis. Lahtinen L, etal., Eur J Neurosci. 2006 Oct;24(7):1935-45. Epub 2006 Oct 16.
36. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Laudes IJ, etal., Am J Pathol. 2002 May;160(5):1867-75.
37. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. Laurell H, etal., World J Gastroenterol. 2006 Jun 7;12(21):3344-51.
38. Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia. Li X, etal., J Virol. 2009 May;83(10):4912-22. doi: 10.1128/JVI.02343-08. Epub 2009 Mar 11.
39. Reductions in mRNA of the neuroprotective agent, neuroserpin, after cerebral ischemia/reperfusion in diabetic rats. Liang W, etal., Brain Res. 2004 Jul 23;1015(1-2):175-80.
40. Nan fang yi ke da xue xue bao = Journal of Southern Medical University Liu BY, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jan;27(1):35-7.
41. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Liu ZH, etal., Biomed Environ Sci. 2005 Aug;18(4):260-4.
42. Activity-dependent release of tissue plasminogen activator from the dendritic spines of hippocampal neurons revealed by live-cell imaging. Lochner JE, etal., J Neurobiol. 2006 May;66(6):564-77. doi: 10.1002/neu.20250.
43. Basic mechanisms and regulation of fibrinolysis. Longstaff C and Kolev K, J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105. doi: 10.1111/jth.12935.
44. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Lu CS, etal., Arthritis Rheum. 2005 Dec;52(12):4018-27.
45. Urokinase redistribution from the secreted to the cell-bound fraction in granulosa cells of rat preovulatory follicles. Macchione E, etal., Biol Reprod. 2000 Apr;62(4):895-903.
46. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Mannucci PM, etal., Br J Haematol. 1992 Sep;82(1):87-93.
47. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome. Mehta P and Parker RI, J Pediatr Hematol Oncol. 2010 Oct;32(7):532-6. doi: 10.1097/MPH.0b013e3181e0d152.
48. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
49. Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats. Mori Y, etal., Endocr J. 2003 Oct;50(5):603-11.
50. Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. Nakasaki T, etal., Am J Hematol. 2000 Jul;64(3):145-50.
51. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
52. The role of proteases in fibronectin matrix remodeling in thyroid epithelial cell monolayer cultures. Nezi L, etal., Biol Chem 2002 Jan;383(1):167-76.
53. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H, etal., Blood Coagul Fibrinolysis. 1992 Aug;3(4):389-93.
54. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. NO_AUTHOR N Engl J Med. 1995 Dec 14;333(24):1581-7.
55. Age-related changes in coagulation, fibrinolysis, and platelet aggregation in male WBN/Kob rats. Nobukata H, etal., Thromb Res. 2000 Jun 15;98(6):507-16.
56. Cloning and characterization of a cDNA for rat tissue-type plasminogen activator. Ny T, etal., DNA 1988 Dec;7(10):671-7.
57. Hormonal regulation of tissue plasminogen activator secretion and mRNA levels in rat granulosa cells. O'Connell ML, etal., J Biol Chem. 1987 Feb 15;262(5):2339-44.
58. Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population? Oguzulgen IK, etal., J Thromb Thrombolysis. 2005 Feb;19(1):61-3.
59. Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children. Olgun H, etal., Blood Coagul Fibrinolysis. 2014 Oct;25(7):726-30. doi: 10.1097/MBC.0000000000000134.
60. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
61. Thrombin activation and increased fibrinolysis in patients with chronic liver disease. Paramo JA, etal., Blood Coagul Fibrinolysis. 1991 Apr;2(2):227-30.
62. Blood brain barrier (BBB) dysfunction associated with increased expression of tissue and urokinase plasminogen activators following peripheral thermal injury. Patel TH, etal., Neurosci Lett. 2008 Oct 31;444(3):222-6. Epub 2008 Aug 13.
63. Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1. Peng WH, etal., J Ethnopharmacol. 2010 Feb 17;127(3):606-13. Epub 2009 Dec 24.
64. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
65. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
66. GOA pipeline RGD automated data pipeline
67. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
68. Comprehensive gene review and curation RGD comprehensive gene curation
69. Role of plasminogen activators during healing after uterine serosal lesioning in the rat. Rout UK and Diamond MP, Fertil Steril 2003 Jan;79(1):138-45.
70. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Sahli D, etal., Thromb Res. 2009 Mar;123(5):701-6. Epub 2008 Oct 21.
71. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. Saidi S, etal., J Stroke Cerebrovasc Dis. 2007 Jul-Aug;16(4):153-9.
72. Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking. Scalettar BA, etal., Dev Neurobiol. 2012 Sep;72(9):1181-95. doi: 10.1002/dneu.20984. Epub 2012 Jun 21.
73. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Sheehan JJ and Tsirka SE, Glia. 2005 Jun;50(4):340-50.
74. Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation. Shin CY, etal., J Neurosci. 2004 Oct 20;24(42):9425-33.
75. Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. Son H, etal., Biochem Biophys Res Commun 2002 Oct 25;298(2):262-8.
76. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
77. Role of tissue plasminogen activator/plasmin cascade in delayed neuronal death after transient forebrain ischemia. Takahashi H, etal., Neurosci Lett. 2005 Jun 10-17;381(1-2):189-93. Epub 2005 Mar 2.
78. Effect of activated protein C on impaired fibrinolysis in rats with obstructive jaundice. Uchino R, etal., Eur Surg Res. 1992;24(5):298-301.
79. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity. Umpaichitra V, etal., Pediatr Res. 2005 Sep;58(3):483-7. Epub 2005 May 18.
80. Epinephrine exerts anticoagulant effects during human endotoxemia. van der Poll T, etal., J Exp Med. 1997 Mar 17;185(6):1143-8.
81. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Van Geet C, etal., Kidney Int. 1998 Oct;54(4):1324-30.
82. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction. Wada T, etal., Thromb Res. 2013 Jul;132(1):e64-9. doi: 10.1016/j.thromres.2013.05.010. Epub 2013 May 30.
83. Additional evidence that the sympathetic nervous system regulates the vessel wall release of tissue plasminogen activator. Wang Y, etal., Blood Coagul Fibrinolysis. 2002 Sep;13(6):471-81.
84. Tissue plasminogen activator for the treatment of intraventricular hematoma: the dose-effect relationship. Wang YC, etal., J Neurol Sci. 2002 Oct 15;202(1-2):35-41.
85. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Wannamethee SG, etal., Diabetes Care. 2008 May;31(5):995-1000. Epub 2008 Jan 30.
86. Elevated plasma tissue plasminogen activator and anti-THP-1 antibodies are independently associated with decreased graft survival in cardiac transplant recipients. Warshofsky MK, etal., Am J Cardiol. 2001 Jul 1;88(1):30-4.
87. Chemical sympathectomy attenuates inflammation, glycocalyx shedding and coagulation disorders in rats with acute traumatic coagulopathy. Xu L, etal., Blood Coagul Fibrinolysis. 2015 Mar;26(2):152-60. doi: 10.1097/MBC.0000000000000211.
88. Impact of beta-adrenoceptor blockade on systemic inflammation and coagulation disturbances in rats with acute traumatic coagulopathy. Xu L, etal., Med Sci Monit. 2015 Feb 12;21:468-76. doi: 10.12659/MSM.893544.
89. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. Yepes M, etal., J Clin Invest 2002 Jun;109(12):1571-8.
90. The role and mechanism of the up-regulation of fibrinolytic activity in painful peripheral nerve injury. Yong N and Guoping C, Neurochem Res. 2009 Mar;34(3):587-92. Epub 2008 Aug 21.
91. Release of tissue-type plasminogen activator by activated rat eggs and its possible role in the zona reaction. Zhang X, etal., Mol Reprod Dev. 1992 May;32(1):28-32. doi: 10.1002/mrd.1080320106.
92. Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia. Zhao G, etal., Neuroreport. 2003 Sep 15;14(13):1689-92.
93. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Zhou H, etal., Thromb Res. 2009;123(3):537-42. Epub 2008 Aug 8.
Additional References at PubMed
PMID:1632457   PMID:1695900   PMID:8186264   PMID:8508955   PMID:12431485   PMID:12694198   PMID:12783121   PMID:14750967   PMID:15019809   PMID:15044208   PMID:15372073   PMID:15486301  
PMID:15489334   PMID:15978259   PMID:16019605   PMID:16051896   PMID:16150423   PMID:16303771   PMID:17299772   PMID:17382917   PMID:17849409   PMID:17953365   PMID:17992606   PMID:18037995  
PMID:18523654   PMID:18714030   PMID:18947492   PMID:18982462   PMID:19152029   PMID:19403340   PMID:19584397   PMID:20026244   PMID:20068577   PMID:20458337   PMID:20596602   PMID:21193004  
PMID:21355198   PMID:21355820   PMID:21412817   PMID:21898905   PMID:21919910   PMID:22071631   PMID:22556277   PMID:22610100   PMID:23258228   PMID:23301636   PMID:23376485   PMID:23378038  
PMID:24129569   PMID:24196407   PMID:25425079   PMID:29304073   PMID:31848365   PMID:34968722   PMID:36283468   PMID:38360257  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81675,943,061 - 76,022,037 (-)NCBIGRCr8
mRatBN7.21669,240,582 - 69,265,177 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1669,240,585 - 69,268,223 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1674,514,320 - 74,538,910 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01677,946,850 - 77,971,428 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01673,195,994 - 73,220,572 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01674,098,263 - 74,122,897 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1674,098,260 - 74,122,889 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01673,730,256 - 73,754,851 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41673,711,323 - 73,736,328 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11673,711,587 - 73,736,593 (-)NCBI
Celera1667,134,451 - 67,159,047 (-)NCBICelera
RH 3.4 Map16644.8RGD
Cytogenetic Map16q12.5NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh38842,174,718 - 42,207,565 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl842,174,718 - 42,207,709 (-)EnsemblGRCh38hg38GRCh38
GRCh37842,032,236 - 42,065,083 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36842,151,393 - 42,184,351 (-)NCBINCBI36Build 36hg18NCBI36
Build 34842,151,911 - 42,184,351NCBI
Celera840,981,190 - 41,014,147 (-)NCBICelera
Cytogenetic Map8p11.21NCBI
HuRef840,559,713 - 40,592,984 (-)NCBIHuRef
CHM1_1842,080,535 - 42,113,811 (-)NCBICHM1_1
T2T-CHM13v2.0842,449,037 - 42,481,874 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39823,247,655 - 23,272,864 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl823,247,743 - 23,272,860 (+)EnsemblGRCm39 Ensembl
GRCm38822,757,722 - 22,782,848 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl822,757,727 - 22,782,844 (+)EnsemblGRCm38mm10GRCm38
MGSCv37823,868,216 - 23,893,320 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36824,223,313 - 24,248,389 (+)NCBIMGSCv36mm8
Celera824,247,228 - 24,272,480 (+)NCBICelera
Cytogenetic Map8A2NCBI
cM Map811.42NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_004955536730,981 - 756,394 (+)EnsemblChiLan1.0
ChiLan1.0NW_004955536730,962 - 754,333 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1-v2760,627,599 - 61,135,005 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan1836,344,912 - 36,377,468 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0841,419,415 - 41,451,951 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1838,864,918 - 38,897,776 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl838,864,918 - 38,897,779 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11623,469,590 - 23,496,013 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1623,974,129 - 24,000,506 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01625,217,768 - 25,244,182 (+)NCBIROS_Cfam_1.0
UMICH_Zoey_3.11623,588,653 - 23,615,286 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01624,152,407 - 24,178,867 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01624,203,090 - 24,229,785 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440494346,519,711 - 46,546,290 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936785476,078 - 503,321 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_004936785476,200 - 503,371 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1711,195,602 - 11,224,032 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11711,195,599 - 11,223,821 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21713,168,730 - 13,197,126 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1840,164,391 - 40,196,627 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl840,163,891 - 40,196,555 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660521,590,000 - 1,622,258 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046247801,028,085 - 1,063,649 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247801,014,429 - 1,063,636 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Plat
224 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:321
Count of miRNA genes:199
Interacting mature miRNAs:219
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1600378Arunc4Aerobic running capacity QTL 40.03exercise endurance trait (VT:0002332)maximum distance run on treadmill (CMO:0001406)1638024580345693Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor depth of invasion (CMO:0001888)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor depth of invasion (CMO:0001888)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor diameter (CMO:0001889)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor diameter (CMO:0001889)161769679182635055Rat
70215Niddm29Non-insulin dependent diabetes mellitus QTL 293.54blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)161900443575226532Rat
8694453Bw172Body weight QTL 1728.330.001retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)162432551369325513Rat
6903294Stl30Serum triglyceride level QTL 302.60.0013blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)162515279370152793Rat
1578768Stresp22Stress response QTL 222.8thymus mass (VT:0004954)thymus wet weight (CMO:0000855)163528887080288870Rat
2293690Bss45Bone structure and strength QTL 455.130.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)163775215682752156Rat
2300163Bmd64Bone mineral density QTL 645.30.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)163775215682752156Rat
7205510Activ5Activity QTL 53.780.00028locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)164239634584729064Rat
8694429Bw164Body weight QTL 16450.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)165272646484729064Rat
8694364Abfw7Abdominal fat weight QTL 712.220.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)165272646484729064Rat
7411648Foco22Food consumption QTL 22150.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)165272646484729064Rat
631525Pia14Pristane induced arthritis QTL 144.4joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)165571108783402471Rat
1298527Arunc2Aerobic running capacity QTL 22.9exercise endurance trait (VT:0002332)maximum distance run on treadmill (CMO:0001406)166853271675029966Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21669,240,722 - 69,240,937 (+)MAPPERmRatBN7.2
Rnor_6.01674,098,404 - 74,098,618NCBIRnor6.0
Rnor_5.01673,730,397 - 73,730,611UniSTSRnor5.0
RGSC_v3.41673,711,459 - 73,711,673UniSTSRGSC3.4
Celera1667,134,587 - 67,134,801UniSTS
RH 3.4 Map16662.2UniSTS
Cytogenetic Map16q12.5UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21669,265,445 - 69,265,608 (-)MAPPERmRatBN7.2
mRatBN7.21669,265,445 - 69,265,608 (+)MAPPERmRatBN7.2
Rnor_6.01674,123,127 - 74,123,289NCBIRnor6.0
Rnor_6.01673,745,362 - 73,745,524NCBIRnor6.0
Rnor_5.01673,377,333 - 73,377,495UniSTSRnor5.0
Rnor_5.01673,755,120 - 73,755,282UniSTSRnor5.0
RGSC_v3.41673,736,597 - 73,736,759UniSTSRGSC3.4
Celera1667,159,316 - 67,159,478UniSTS
RH 3.4 Map16663.8UniSTS
Cytogenetic Map16q12.5UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21669,240,906 - 69,241,079 (+)MAPPERmRatBN7.2
Rnor_6.01674,098,588 - 74,098,760NCBIRnor6.0
Rnor_5.01673,730,581 - 73,730,753UniSTSRnor5.0
RGSC_v3.41673,711,643 - 73,711,815UniSTSRGSC3.4
Celera1667,134,771 - 67,134,943UniSTS
RH 3.4 Map16644.8UniSTS
Cytogenetic Map16q12.5UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21669,240,297 - 69,240,437 (+)MAPPERmRatBN7.2
Rnor_6.01674,097,979 - 74,098,118NCBIRnor6.0
Rnor_5.01673,729,972 - 73,730,111UniSTSRnor5.0
RGSC_v3.41673,711,034 - 73,711,173UniSTSRGSC3.4
Celera1667,134,162 - 67,134,301UniSTS
RH 3.4 Map16689.61UniSTS
Cytogenetic Map16q12.5UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 43 21 6 8 6 2 2 74 35 33 11 2
Low 36 35 11 35 6 9 8 6
Below cutoff


RefSeq Acc Id: ENSRNOT00000025763   ⟹   ENSRNOP00000025764
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1669,240,585 - 69,265,111 (-)Ensembl
Rnor_6.0 Ensembl1674,098,260 - 74,122,889 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000088219   ⟹   ENSRNOP00000071993
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1669,240,585 - 69,268,223 (-)Ensembl
Rnor_6.0 Ensembl1673,755,539 - 73,763,312 (+)Ensembl
RefSeq Acc Id: NM_013151   ⟹   NP_037283
Rat AssemblyChrPosition (strand)Source
GRCr81675,943,066 - 75,967,656 (-)NCBI
mRatBN7.21669,240,587 - 69,265,177 (-)NCBI
Rnor_6.01674,098,268 - 74,122,858 (-)NCBI
Rnor_5.01673,730,256 - 73,754,851 (-)NCBI
RGSC_v3.41673,711,323 - 73,736,328 (-)RGD
Celera1667,134,451 - 67,159,047 (-)RGD
RefSeq Acc Id: XM_006253347   ⟹   XP_006253409
Rat AssemblyChrPosition (strand)Source
GRCr81675,943,061 - 75,967,513 (-)NCBI
mRatBN7.21669,240,582 - 69,264,980 (-)NCBI
Rnor_6.01674,098,263 - 74,122,761 (-)NCBI
Rnor_5.01673,730,256 - 73,754,851 (-)NCBI
RefSeq Acc Id: XM_063275098   ⟹   XP_063131168
Rat AssemblyChrPosition (strand)Source
GRCr81675,943,061 - 76,022,037 (-)NCBI
RefSeq Acc Id: NP_037283   ⟸   NM_013151
- Peptide Label: precursor
- UniProtKB: P19637 (UniProtKB/Swiss-Prot),   A6IW59 (UniProtKB/TrEMBL),   A0A0G2K1V0 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006253409   ⟸   XM_006253347
- Peptide Label: isoform X1
- Sequence:
RefSeq Acc Id: ENSRNOP00000025764   ⟸   ENSRNOT00000025763
RefSeq Acc Id: ENSRNOP00000071993   ⟸   ENSRNOT00000088219
RefSeq Acc Id: XP_063131168   ⟸   XM_063275098
- Peptide Label: isoform X2
Protein Domains
EGF-like   Fibronectin type-I   Kringle   Peptidase S1

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-A0A0G2K1V0-F1-model_v2 AlphaFold A0A0G2K1V0 1-309 view protein structure
AF-P19637-F1-model_v2 AlphaFold P19637 1-559 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13700183
Promoter ID:EPDNEW_R10707
Type:multiple initiation site
Description:plasminogen activator, tissue type
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01674,122,858 - 74,122,918EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3342 AgrOrtholog
BioCyc Gene G2FUF-10883 BioCyc
Ensembl Genes ENSRNOG00000019018 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOG00000060898 Ensembl
  ENSRNOG00060027808 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000025763.7 UniProtKB/TrEMBL
  ENSRNOT00000088219.2 UniProtKB/TrEMBL
  ENSRNOT00060048368 UniProtKB/Swiss-Prot
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Complement Module, domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Laminin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro EGF-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Fibronectin_type1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA_chymotrypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1A UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tissue_plasm_act UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_HIS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25692 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PANTHER PTHR24264:SF42 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam EGF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  fn1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Plat PhenoGen
PIRSF Tissue_plasm_act UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  KRINGLE UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE EGF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FN1_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FN1_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  KRINGLE_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  KRINGLE_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_HIS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000019018 RatGTEx
  ENSRNOG00000060898 RatGTEx
  ENSRNOG00060027808 RatGTEx
SMART EGF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FN1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SM00130 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tryp_SPc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP FnI-like domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF50494 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57440 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  P19637 ENTREZGENE, UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2021-03-09 Plat  plasminogen activator, tissue type  LOC100910418  tissue-type plasminogen activator-like  Data merged from RGD:6498623 737654 PROVISIONAL
2016-01-25 Plat  plasminogen activator, tissue type  Plat  plasminogen activator, tissue  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2012-07-05 LOC100910418  tissue-type plasminogen activator-like      Symbol and Name status set to provisional 70820 PROVISIONAL
2002-06-10 Plat  Plasminogen activator, tissue      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_drugs Neuroserpin inhibits its expression in the neurons resulting in the delay of seizure activity by blocking excitotoxin-induced cell death 628337
gene_expression expressed in the brain and central nervous system 628337
gene_process has a role in the central nervous system during processes which require neuronal plasticity 628337
gene_product member of the serine proteinase family 628337
gene_transcript comprised of 14 exons; promoter contains a consensus cAMP-responsive element 729556